

Supplementary Materials

Different Inhibitory Potencies of Oseltamivir Carboxylate, Zanamivir, and Several Tannins on Bacterial and Viral Neuraminidase as Assessed in a Cell-Free Fluorescence-Based Enzyme Inhibition Assay


Stefanie Quosdorf¹, Anja Schuetz² and Herbert Kolodziej¹

¹ Freie Universität Berlin, Institute of Pharmacy, Königin-Luise-Str. 2+4, 14195 Berlin, Germany

² Max-Delbrück-Centrum for Molecular Medicine, Helmholtz-Protein Sample Production Facility, Robert-Rössle-Str. 10, 13125 Berlin, Germany

Dedicated to the late Professor emeritus Takuo Okuda

A



B




Figure S1. Co-crystal structure of bacterial *Vibrio cholerae* NA in complex with (A) zanamivir (PDB code 6EKU, this study) and (B) oseltamivir carboxylate (PDB code 6EKS, this study) with enlarged representations of the 2Fo-Fc electron density maps for the bound inhibitors, contoured at 1.0 σ . The bound inhibitor is shown as stick model, VCNA as cartoon model (yellow).

H1N1-NA	SVKLÁGNSSLCPVSGWATYISKDNSVIRIGSKGDVFVIREPFTISC...SPLE	128
VCNA	GSSNTDGVAAYRDIKFEIQGDVIFRGP.....DRIPSTIVASSVTPGV	237
consensusf.I.....R.P.I.....tP..	
H1N1-NA	CRTFFFLTQGALLNDKHSNGTIKDRSPYRTLMSCPIGEVP.....S	168
VCNA	VTAFAEKRVGG.....GDPGALSNNTNDIITRTRSDGGITWDTELNLTE	280
consensus	...F.....g.....G.....S.....iit.....d.....	
H1N1-NA	PYNSRFESVAWSASACHDG..INWLTIGISGPDNGAVAVLKYNG.....	210
VCNA	QINVSDEFDFSDPRPIYDSSNTVLVSYARWPTDAAQNGDRIKPWMPNGI	330
consensus	..N...E.....D.....L.....P..aA.....r.....	
H1N1-NA	.ITDTIKSWRNINILRTQESEACV.....NGSCFTVMTDGPSNGQ	250
VCNA	KTGNTMSLYGNASVNPQPGHGITLTRQQNISGSQNGRLIYPAIVLDR.FF	579
consensus	...Tm.y.N.v.....l.....NG.....	
H1N1-NA	ASYKIFRIEKG..KIVKSVEMNAP.....NYHYEECSQYPS.SE	287
VCNA	LNVMISIYDDGGSNWQTGSTLPIPFWRKSSILETLEPS.EADMVELQNGD	629
consensusd.G.....l..P.....E.....d	
H1N1-NA	ITCVCRDNWH.....GSRPWPVSFNQ.NLEYQIGYICSGIFGDNPRPN	329
VCNA	LLLTARLDFNQIVNGVNYSPRQQFLSKDGGITWSLLEANNANVFSNIS..	677
consensus	l.....R..f.....S.R.....i.w.l.....a.....N....	
H1N1-NA	DKTGSCGPVSSNGANGVKGFSFKYG.....NGVWIG....RTKSISSRNG	370
VCNATGTVDASITRFEQSDGSHFLFTNPQGNPAGTNGRQN	714
consensusV.a..rf.....l.....Rq.	
H1N1-NA	FEMIWDPNGWGTGTDNNSFIKQDIVGİNNEWSGYSGSFVQHPÉLTGLDCIRP	420
VCNA	LGLWFSFDE....GVTWKGPQLV..NGASAYSDIYQLDS.....ENA	751
consensus	..l.f.....w.....lV..N..SaYS..y.....	
H1N1-NA	CFWVELIRGRPKENTIWTSGSSISFCGVNSDITVGWS	456
VCNA	IVIVETDN.....SNMRILRMPITLLKQKLT	777
consensus	...VE.....S...I...i.....t	

Figure S2. Structure-based amino acid sequence alignment of *Vibrio cholerae* NA (1W0O) and influenza virus H1N1 A/California/04/2009 NA (3NSS). Identical amino acid residues are highlighted in blue, similar amino acid residues in light blue.

Table S1. Concentration–effect relationship parameters and combination index (CI) values of zanamivir and EPs® 7630 alone and in combinations for the inhibition of the bacterial VCNA calculated for exclusivity and non-exclusivity.

compound		CI ₅₀	CI ₇₅	CI ₉₀	CI ₉₅	CI _{wt}	combined effect
zanamivir		–	–		–	–	–
EPs® 7630		–	–		–	–	–
ratio of zanamivir/ EPs® 7630							
5:1	exclusive	1.1 ± 0.1	0.7 ± 0.1	0.5 ± 0.1	0.4 ± 0.1	0.5	synergistic
	non-exclusive	1.3 ± 0.1	0.8 ± 0.01	0.5 ± 0.06	0.4 ± 0.07	0.6	synergistic
10:1	exclusive	0.9 ± 0.1	0.7 ± 0.1	0.6 ± 0.1	0.5 ± 0.1	0.6	synergistic
	non-exclusive	1.1 ± 0.1	0.8 ± 0.1	0.6 ± 0.1	0.5 ± 0.1	0.7	moderate synergistic
1:1	exclusive		1.8 ± 0.08	1.5 ± 0.08	1.3 ± 0.08	1.6	antagonistic
	non-exclusive	2.6 ± 0.2	2.1 ± 0.01	1.6 ± 0.02	1.4 ± 0.06	1.7	antagonistic
1:5	exclusive	0.7 ± 0.1	0.8 ± 0.01	1.0 ± 0.1	1.1 ± 0.1	1.0	additive
	non-exclusive	0.7 ± 0.1	0.8 ± 0.1	1.0 ± 0.1	1.2 ± 0.1	1.0	additive
1:10	exclusive	0.7 ± 0.1	0.8 ± 0.1	0.8 ± 0.1	0.9 ± 0.1	0.8	moderate synergistic
	non-exclusive	0.7 ± 0.1	0.8 ± 0.1	0.8 ± 0.1	0.9 ± 0.1	0.8	moderate synergistic

CI values are expressed as mean ± SD (n= 3-6 independent experiments). The weighted CI (CI_{wt}) is calculated on the basis of the representative CI values at effect levels $f_a > 0.5$.

Table S2. Comparison of key viral H1N1-NA–ligand interactions

Protein residue	Ligand group	Distance (Å) zanamivir	Distance (Å) oseltamivir acid	Molecular interactions
Arg 118	2-/1-carboxy-	2.76 / 3.46	2.84 / 3.50	1 ; 4
Glu 119	4-guanidino-/5-amino-	3.22	2.80	2 ; 3
Asp 151	4-guanidino-/5-amino-	2.96/3.01	3.19	2 ; 3
Arg 152	carbonyl- (5-/4-acetamido-)	2.86	2.81	1
Arg 156	4-guanidino-/5-amino-	3.26	-	2
Trp 178	4-guanidino-/5-amino-	2.73/3.11	-	2
Glu 227	4-guanidino-/5-amino-	3.12	-	2 ; 3
Glu 276	6-(1',2',3')-trihydroxypropyl-	2.72 / 2.59	-	2
Arg 292	2-/1-carboxy-	3.19 / 3.24	3.10 / 3.29	1 ; 4
Arg 371	2-/1-carboxy-	2.70 / 2.94	2.64 / 2.83	1 ; 4
Tyr 406	2-/1-carboxy-	-	3.47	1
Tyr 406	ring oxygen	3.14	-	1

Here, we analyzed the published co-crystal structures of H1N1-NA in complex with zanamivir and oseltamivir carboxylate (PDB ID codes 3TI5 and 3TI6). Hydrogen bond distances are indicated as derived from COOT analysis. Type of interaction: 1) hydrogen bond (acceptor), 2) hydrogen bond (donor), 3) positive ionization, 4) negative ionization.

Table S3. Comparison of key bacterial VCNA–ligand interactions.

Protein residue	Ligand group	Distance (Å) zanamivir	Distance (Å) oseltamivir acid	Molecular interactions
Arg 224	2-/1-carboxy-	2.89 / 3.04	2.77 / 3.27	1 ; 4
Glu 243	4-guanidino-/5-amino-	2.77 / 3.33	-	2 ; 3
Arg 245	4-guanidino-/5-amino-	2.87 / 3.43	3.39	2
Asp 250	4-guanidino-/5-amino-	2.97 / 3.51	2.97	2 ; 3
Asp 292	4-guanidino-/5-amino-	3.11 / 3.41	-	2 ; 3
Asn 318	carbonyl- (5-/4-acetamido-)	3.37 / 3.54	3.59	1
Asn 318	6-(1',2',3')-trihydroxypropyl-	2.70 / 3.47	-	2
Arg 635	2-/1-carboxy-	2.97 / 3.31	3.00 / 3.19	1 ; 4
Asp 637	6-(1',2',3')-trihydroxypropyl-	2.71 / 3.12	-	2
Arg 712	2-/1-carboxy-	2.85 / 2.87	2.74 / 2.93	1 ; 4
Tyr 740	ring system	3.18	-	1

Here, we analyzed the co-crystal structures of bacterial VCNA in complex with zanamivir and oseltamivir carboxylate, determined in this study (PDB ID codes 6EKU and 6EKS). Hydrogen bond distances are indicated as derived from COOT analysis. Type of interaction: 1) hydrogen bond (acceptor), 2) hydrogen bond (donor), 3) positive ionization, 4) negative ionization.